News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Metastatix, Inc. Commences Phase 1 Clinical Trial of MSX-122 in Cancer Patients


12/5/2007 12:25:55 PM

ATLANTA--(BUSINESS WIRE)--Metastatix, Inc., an emerging pharmaceutical company focused on the development of small molecule therapeutics, today announced the commencement of a Phase 1 study with its drug candidate, MSX-122, in patients with late-stage solid tumors. The study is being conducted at The University of Texas M.D. Anderson Cancer Center in Houston, Texas.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES